NMRA-140 is under clinical development by Neumora Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect NMRA-140’s likelihood of approval (LoA) and phase transition for Major Depressive Disorder took place on 12 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NMRA-140 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
NMRA-140 is under development for the treatment of major depressive disorder (MDD) with anhedonia. The drug candidate is a small molecule that acts by targeting kappa-type opioid receptor (KOR). It is administered through oral route.
Neumora Therapeutics overview
Neumora Therapeutics formerly RBNC Therapeutics, is a biotechnology company that uses data science and neuroscience to develop precision medications to treat brain diseases. Neumora Therapeutics is headquartered in Watertown, Massachusetts, the US.
Quick View NMRA-140 LOA Data
|Highest Development Stage|